NASDAQ:APTO - Aptose Biosciences Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $11.33
  • Forecasted Upside: 233.33 %
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
▼ -0.07 (-2.02%)
1 month | 3 months | 12 months
Get New Aptose Biosciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for APTO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for APTO

Average Price Target: $11.33
▲ +233.33% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Aptose Biosciences in the last 3 months. The average price target is $11.33, with a high forecast of $14.00 and a low forecast of $9.00. The average price target represents a 233.33% upside from the last price of $3.40.


The current consensus among 6 polled investment analysts is to buy stock in Aptose Biosciences. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/24/2021OppenheimerBoost Price TargetOutperform$8.00 ➝ $9.00High
2/22/2021JonestradingInitiated CoverageBuy$14.00High
10/20/2020Canaccord GenuityReiterated RatingBuy$13.00High
10/19/2020Cantor FitzgeraldInitiated CoverageOverweight$10.00High
9/22/2020Alliance Global PartnersInitiated CoverageBuy$12.00High
6/23/2020Piper SandlerReiterated RatingOverweight$10.00High
6/14/2020OppenheimerInitiated CoverageBuy$9.00High
6/12/2020Maxim GroupInitiated CoverageBuy$16.00High
6/12/2020HC WainwrightReiterated RatingBuy$9.00Medium
4/27/2020HC WainwrightReiterated RatingBuy$9.00Medium
3/4/2020Canaccord GenuityReiterated RatingBuy$13.00High
2/20/2020Maxim GroupInitiated CoverageBuy$16.00High
2/6/2020HC WainwrightBoost Price TargetBuy$6.00 ➝ $9.00Low
1/9/2020Piper SandlerInitiated CoverageOverweight$10.00High
8/7/2019HC WainwrightLower Price TargetBuy$8.50 ➝ $6.00Low
5/23/2019Roth CapitalReiterated RatingBuyHigh
4/2/2019HC WainwrightSet Price TargetBuy$9.00Low
3/22/2019HC WainwrightSet Price TargetBuy$9.00Medium
3/1/2019Royal Bank of CanadaInitiated CoverageOutperform ➝ Outperform$6.00Medium
1/25/2019CitigroupInitiated CoverageOutperform$6.00High
1/24/2019OppenheimerInitiated CoverageOutperform$6.00 ➝ $6.00High
12/13/2018HC WainwrightSet Price TargetBuy$9.00High
12/12/2018Roth CapitalReiterated RatingBuyHigh
12/3/2018HC WainwrightSet Price TargetBuy$9.00Medium
11/26/2018HC WainwrightSet Price TargetBuy$9.00High
11/16/2018B. RileyInitiated CoverageBuy ➝ Buy$5.00High
11/7/2018HC WainwrightSet Price TargetBuy$9.00Medium
10/10/2018HC WainwrightSet Price TargetBuy$9.00Low
8/8/2018HC WainwrightReiterated RatingBuy$9.00Medium
6/29/2018HC WainwrightReiterated RatingBuy$8.50Low
5/13/2018HC WainwrightSet Price TargetBuy$6.00Medium
5/7/2018HC WainwrightSet Price TargetBuy$6.00Low
4/16/2018Roth CapitalSet Price TargetBuy$6.00Low
4/16/2018HC WainwrightSet Price TargetBuy$6.00Low
3/28/2018HC WainwrightSet Price TargetBuy$6.00High
3/7/2018HC WainwrightSet Price TargetBuy$6.00High
12/13/2017HC WainwrightReiterated RatingBuy ➝ Buy$4.00 ➝ $6.00High
11/15/2017Canaccord GenuitySet Price TargetBuy$7.00N/A
11/15/2017HC WainwrightSet Price TargetBuy$4.00N/A
10/30/2017HC WainwrightSet Price TargetBuy$4.00N/A
10/23/2017Roth CapitalReiterated RatingBuy ➝ Buy$5.00N/A
9/7/2017HC WainwrightUpgradeNeutral ➝ Buy$1.00 ➝ $4.00High
6/8/2017HC WainwrightInitiated CoverageHoldHigh
6/8/2017Rodman & RenshawInitiated CoverageNeutral ➝ NeutralHigh
5/12/2017Canaccord GenuityReiterated RatingBuy$7.00Low
1/23/2017Canaccord GenuityReiterated RatingBuy$7.00N/A
11/16/2016Royal Bank of CanadaLower Price TargetOutperform$18.00 ➝ $12.00N/A
10/15/2016Canaccord GenuityReiterated RatingBuy$7.00N/A
10/14/2016Roth CapitalReiterated RatingBuy$8.00N/A
9/13/2016Royal Bank of CanadaReiterated RatingOutperformN/A
6/25/2016Royal Bank of CanadaReiterated RatingOutperform$23.00N/A
(Data available from 6/20/2016 forward)
Aptose Biosciences logo
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.
Read More

Today's Range

Now: $3.40
Low: $3.38
High: $3.53

50 Day Range

MA: $5.00
Low: $3.38
High: $5.64

52 Week Range

Now: $3.40
Low: $3.33
High: $7.30


1,172,180 shs

Average Volume

2,867,655 shs

Market Capitalization

$302.43 million

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Aptose Biosciences?

The following equities research analysts have issued reports on Aptose Biosciences in the last year: Alliance Global Partners, Canaccord Genuity, Cantor Fitzgerald, Jonestrading, Oppenheimer Holdings Inc., Piper Sandler, and Zacks Investment Research.
View the latest analyst ratings for APTO.

What is the current price target for Aptose Biosciences?

6 Wall Street analysts have set twelve-month price targets for Aptose Biosciences in the last year. Their average twelve-month price target is $11.33, suggesting a possible upside of 233.3%. Jonestrading has the highest price target set, predicting APTO will reach $14.00 in the next twelve months. Oppenheimer Holdings Inc. has the lowest price target set, forecasting a price of $9.00 for Aptose Biosciences in the next year.
View the latest price targets for APTO.

What is the current consensus analyst rating for Aptose Biosciences?

Aptose Biosciences currently has 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe APTO will outperform the market and that investors should add to their positions of Aptose Biosciences.
View the latest ratings for APTO.

What other companies compete with Aptose Biosciences?

How do I contact Aptose Biosciences' investor relations team?

Aptose Biosciences' physical mailing address is 251 CONSUMERS ROAD SUITE 1105, TORONTO A6, M2J 4R3. The biotechnology company's listed phone number is 858-926-2730 and its investor relations email address is [email protected] The official website for Aptose Biosciences is